Breast Biopsy Devices Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Breast Biopsy Devices Market size was valued at USD 1.8 billion in 2022 and is anticipated to register a CAGR of over 6.8% between 2023 and 2032. These devices are medical instruments or tools used by healthcare professionals to obtain tissue samples from the breast for diagnostic purposes. For instance, a report in the Journal of Clinical Oncology projects a 31% rise in new global female breast cancer cases, from 2,260,127 in 2020 to an estimated 2,964,197 cases in 2040.
Furthermore, an improved reimbursement landscape for breast biopsy procedures and associated diagnostic tests incentivizes healthcare providers and patients to utilize these services.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Breast Biopsy Devices Market size in 2022: | USD 1.8 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 6.8 |
| 2023 Value Projection: | USD 3.6 Billion |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 679 |
| Tables, Charts & Figures: | 836 |
| Segments Covered: | Product, Technique, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The COVID-19 storm had cast a shadow over the market, disrupting healthcare services, triggering safety apprehensions among patients, leading to supply chain hiccups, constraining healthcare budgets, and diverting resources to the COVID-19 research front.
Continuous advancements in biopsy technologies and equipment, such as more precise and minimally invasive techniques, improved imaging capabilities, and enhanced tissue sampling methods. For instance, Mammotome's Mammotome Elite Tetherless Biopsy System uses dual vacuum-assisted technology for precise breast biopsies and features an ergonomic design with multiple buttons for flexibility, enhancing efficiency in complex procedures.
The market by product is categorized into breast biopsy guidance systems, needle-based breast biopsy guns, breast biopsy needles, breast biopsy forceps and other products. The needle-based breast biopsy guns segment is bifurcated into vacuum-assisted biopsy (VAB) devices, fine needle aspiration biopsy (FNAB) devices, and core needle biopsy (CNB) devices. This segment garnered USD 568 million revenue size in the year 2022 and is projected to have the fastest-growing CAGR in the forecast period.
Based on technique, the breast biopsy devices market is segmented into image guided biopsy and liquid biopsy. The image guided biopsy segment is further bifurcated into MRI guided breast biopsy, ultrasound guided breast biopsy, mammography guided stereotactic biopsy and other image guided biopsies. This segment garnered USD 1.3 billion revenue size in the year 2022.
Based on end-use, the breast biopsy devices market is segmented into hospitals and ambulatory surgical centres. The hospitals segment garnered USD 1.1 billion revenue size in the year 2022.
U.S. breast biopsy devices market accounted for USD 649 million revenue size in 2022.
The breast biopsy devices industry is consolidated, with key players including, Medtronic plc, Hologic Inc, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in January 2021, Hologic, Inc., acquired SOMATEX Medical Technologies GmbH, thereby strengthening its breast marker portfolio and consolidating its position in biopsy site markers and localization technologies. The strategic move also extended Hologic's sales presence in Europe by expanding its direct channel in Germany and augmenting its network of regional and international distributor partners.
Some of the eminent market participants operating in the breast biopsy devices industry include:
By Product, 2018 – 2032 (USD Million and Units)
By Technique, 2018 – 2032 (USD Million)
By End-use, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
Stryker Corporation, Boston Scientific Corporation, FUJIFILM Holdings Corporation, Argon Medical Devices, Inc, Hologic Inc, Cook Group Incorporated, Becton, Dickinson and Company (BD), Medtronic plc, Olympus Corporation, Cardinal Health, and INRAD Inc among others.
The global breast biopsy devices market was valued at USD 1.8 billion in 2022 and is estimated to reach USD 3.6 billion by 2032, backed by surge in breast cancer cases, favorable reimbursement policies, awareness about benefits of early detection.
The hospitals segment generated USD 1.1 billion in 2022 and will continue to drive demand as these healthcare settings leverage advanced infrastructure and skilled professionals to integrate sophisticated biopsy procedures seamlessly, gaining patient
U.S. market accounted for USD 649 million in 2022 and is predicted to witness substantial growth through 2032, primarily due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and proactive breast cancer awareness programs.